+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs



Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs



Gut 51(3): 336-343



Background and aims: A past history of peptic ulceration increases the risk of an ulcer developing during non-steroidal anti-inflammatory drug (NSAID) use. Whether this is due to Helicobocter pylori infection or to reactivation of the original lesion is unclear. Methods: We used multivariate regression analyses of three large similar trials to identify factors that placed patients at high risk of ulcer development or relapse. We compared the efficacy of omeprazole 20 mg daily, misoprostol 200 mug twice daily, and ranitidine 150 mg twice daily in preventing ulcers and erosions at different sites and in patients who were H. pylori positive and negative. Results: Patients with endoscopic lesions (which healed) initially were significantly more likely than those without to develop further erosions or ulcers during treatment (rate ratio 2.12, 1.07-4.17). Risk mounted further with ulcers versus erosions, particularly those that had been slow to heal. There was a highly significant tendency for the relapse lesion to replicate the site and type of the original lesion (mean odds ratios ranging from 3 to 14). Treatment failure was significantly less likely with omeprazole than with placebo, misoprostol, or ranitidine. This advantage was especially evident in H. pylori positive patients receiving acid suppression (5.7% v 16.6% for gastric ulcer with omeprazole). Conclusions: Relapse of lesions in patients taking NSAIDs was highly site and type specific and not adversely affected by H. pylori status. This strongly implies that local mucosal factors predispose to ulcer development in patients taking NSAIDs. Identification of the responsible mucosal changes would aid understanding and could promote better treatment.

(PDF emailed within 0-6 h: $19.90)

Accession: 011278181

Download citation: RISBibTeXText

PMID: 12171953

DOI: 10.1136/gut.51.3.336


Related references

Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 34(6): 748-751, 1993

Non-steroidal anti-inflammatory drugs associated with gastroduodenal injury and Helicobacter pylori. European Journal of Gastroenterology and Hepatology 6 Suppl 1: S109-S112, 1994

Helicobacter pylori infection and gastroduodenal injury by non-steroidal anti-inflammatory drugs. Scandinavian Journal of Gastroenterology. Supplement 187: 91-97, 1991

Gastroduodenal lesions and non-steroidal anti-inflammatory drugs: Which is the role of Helicobacter pylori in this relation?. Revista Espanola de Enfermedades Digestivas 90(9): 655-664, Sept, 1998

Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut 51(3): 344-350, 2002

Bleeding gastroduodenal ulcers in patients without Helicobacter pylori infection and without exposure to non-steroidal anti-inflammatory drugs. Vojnosanitetski Pregled 71(2): 183-190, 2015

Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs. Gut 46(3): 310-311, 2000

Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non-steroidal anti-inflammatory drugs. Alimentary Pharmacology and Therapeutics 4(5): 515-522, 1990

Helicobacter pylori, non-steroidal anti-inflammatory drugs and gastroduodenal ulceration. Medical Science Research 23(11): 765-766, 1995

Effect of helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients using non steroidal anti inflammatory drugs. Gut 32(10): A1257, 1991

Gastroduodenal lesions and non-steroidal anti-inflammatory agents. What role does Helicobacter pylori play in this relationship?. Revista Espanola de Enfermedades Digestivas 90(9): 655-664, 1998

Helicobacter pylori, non-steroidal anti-inflammatory drugs and smoking in risk pattern of gastroduodenal ulcers. Scandinavian Journal of Gastroenterology 38(9): 923-930, 2003

Gastric and duodenal mucosal blood flow in patients receiving non steroidal anti inflammatory drugs influence of age smoking ulceration and helicobacter pylori. Gut 32(10): A1221, 1991

Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs--influence of age, smoking, ulceration and Helicobacter pylori. Alimentary Pharmacology and Therapeutics 7(1): 41-45, 1993